Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $37,617 | $61,289 |
| General and administrative | 8,494 | 5,483 |
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s G&A?
- ArriVent BioPharma, Inc. (AVBP) reported G&A of $8.49M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s G&A changed year-over-year?
- ArriVent BioPharma, Inc.'s G&A increased by 54.9% year-over-year, from $5.48M to $8.49M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s G&A?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s G&A has grown at a 57.8% compound annual growth rate (CAGR), from $9.71M to $24.18M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about ArriVent BioPharma, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude